Insights
Long-form essays drawn from the 2026 Icelandic Elements whitepaper, field reporting from European trade shows, and clinical-commercial commentary.
Strip out the marketing language, and the case for Icelandic botanicals in cannabinoid formulation is unusually rigorous. Volcanic-soil phytochemistry, extreme-environment stress response, and a small number of actives with real clinical rationale.
Most commentary treats the UK and the EU as two cannabinoid markets. They are one system pulled apart. For operators, the friction is the opportunity, but only if someone is actually moving between the two sides.
There is a gap at the heart of the European cannabis industry, and it is not where the industry thinks it is. Notes on women's wellness, the endocannabinoid system, and the commercial opportunity in plain view.
The endocannabinoid system is not an autonomous regulator in women. It is deeply co-regulated by oestrogen in ways male-default medical research has systematically overlooked. What that means for clinicians, formulators, and operators.
More where this came from
If a piece landed, tell me why. If it missed, tell me that too. I reply within a working day.
Or email directly
paul@nilsenborrell.com